Phaseline

Companies › Arcturus Therapeutics

Arcturus Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Metabolic and endocrine, Respiratory; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ARCT-032
CFTR mRNA formulated in lipid nanoparticles
CFTRPhase 2Cystic FibrosisJun 2027
ARCT-810
Ornithine Transcarbamylase (OTC) mRNA in lipid nanoparticle formulation
OTCPhase 2OTC Deficiency–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06488313ARCT-810Phase 2OTC DeficiencyMetabolic and endocrineJun 2026
NCT06747858ARCT-032Phase 2Cystic FibrosisRespiratoryJun 2027

From the company's SEC filings

Cash of $185m on 2026-09-30; operating cash outflow about $62m a year; runway about 36 months at that burn, to Sep 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

OTC (1) CFTR (1)

Companies with the same targets

Vertex Pharmaceuticals CAMP4 Therapeutics Ultragenyx Pharmaceutical iECURE Napo Pharmaceuticals 4D Molecular Therapeutics ReCode Therapeutics Napo Therapeutics Qanatpharma Krystal Biotech

Companies built like this

Mannkind Mediar Therapeutics Shanghai Novamab Biopharmaceuticals Blue Blood Biotech Hangzhou Sciwind Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.